We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IVVD:NASDAQInvivyd, Inc. Analysis

Data as of 2026-05-22 - not real-time

$1.11

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Invivyd is trading at $1.11, well beneath its 20‑day (≈$1.35), 50‑day (≈$1.46) and 200‑day (≈$1.68) moving averages, with an RSI of 35.7 and a bearish MACD histogram, signaling short‑term momentum weakness and heightened volatility of roughly 94% coupled with a beta above 2, which amplifies market swings.
Despite the technical headwinds, the company posted a 22% year‑over‑year increase in PEMGARDA product revenue to $13.7 million, maintains an impressive 93% gross margin, and holds $184 million in cash against modest debt, supporting a strong‑buy consensus and a median 12‑month target of $10, though operating losses and negative free cash flow remain concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Technical indicators show bearish momentum
  • Upcoming clinical trial updates could shift sentiment
  • Strong cash position provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 22% and high gross margins
  • Progress in VYD2311 Phase III trial and product expansion
  • Analyst consensus of strong‑buy and target price far above current level

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term market potential for antiviral monoclonal antibodies
  • Robust cash reserves to fund R&D and commercialization
  • Significant upside implied by target price versus current valuation

Key Metrics & Analysis

Financial Health

Revenue Growth21.60%
Profit Margin-138.90%
P/E Ratio-1.9
ROE-60.34%
ROA-29.59%
Debt/Equity4.25
P/B Ratio1.3
Op. Cash Flow$-78718000
Free Cash Flow$-50099752
Industry P/E27.3

Technical Analysis

TrendBearish
RSI35.7
Support$1.02
Resistance$1.58
MA 20$1.35
MA 50$1.46
MA 200$1.68
MACDBearish
VolumeIncreasing
Fear & Greed Index91.55

Valuation

Target Price$10.00
Upside/Downside800.90%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.33
Volatility94.64%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.